Status:

COMPLETED

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines

Lead Sponsor:

JHM BioPharma (Tonghua) Co. , Ltd.

Conditions:

Moderate to Severe Glabellar Lines

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

PHASE2

Brief Summary

This is a phase 1/2, multicenter, randomized, double-blind, active-controlled and placebo-controlled study to evaluate safety, immunogenicity and efficacy of JHM03 for the treatment of moderate to sev...

Eligibility Criteria

Inclusion

  • Male or female subjects between 18 and 65 years of age.
  • Moderate to severe glabellar lines at maximum frown at baseline.

Exclusion

  • Previous use of any botulinum toxin within 6 months prior to screening, or plan to use any botulinum toxin during the study.
  • Use of medications that affect neuromuscular transmission within 4 weeks prior to screening, such as muscle relaxant,aminoglycoside antibiotics,anticholinergic drugs,benzodiazepines,etc.
  • Suffering from any neurological disorders that increase the risk of exposure to botulinum toxin type A, including peripheral motor nerve diseases (such as amyotrophic lateral sclerosis and motor neuropathy), as well as neuromuscular junction diseases (such as Lambert-Eaton syndrome and myasthenia gravis).
  • Known allergy or hypersensitivity to any component of the study products.
  • Use of any non-steroid anti-inflammatory drug or anticoagulant within 1 week prior to study treatment.
  • History of alcohol or drug abuse.

Key Trial Info

Start Date :

January 19 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 9 2024

Estimated Enrollment :

190 Patients enrolled

Trial Details

Trial ID

NCT06199336

Start Date

January 19 2024

End Date

September 9 2024

Last Update

April 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Guangdong Second Provincial General Hospital

Guangzhou, Guangdong, China

A Phase I/II, Randomized, Double-blind, Placebo, and Active Controlled Clinical Study to Evaluate the Safety, Tolerability, Immunogenicity, and Preliminary Efficacy of JHM03 in Subjects With Moderate to Severe Glabellar Lines | DecenTrialz